Related Experiment Videos
HMG-CoA reductase inhibitors: Is the endothelium the main target?
P Puddu1, G M Puddu, A Muscari
1Department of Internal Medicine, Cardioangiology and Hepatology, Bologna University, S. Orsola-Malpighi Hospital, Bologna, Italy. amuscari@med.unibo.it
Insights
Statins may primarily target endothelial cells, improving cardiovascular health by addressing endothelial dysfunction. This suggests endothelial cells are a key focus for statin therapy in various cholesterol conditions.
Area of Science:
- Cardiovascular Science
- Endothelial Biology
- Pharmacology
Background:
- Endothelial dysfunction is an early indicator of atherosclerosis, linked to cardiovascular disease progression.
- Abnormalities in endothelium-derived factors like nitric oxide and endothelin-1 contribute to endothelial dysfunction.
- Major risk factors induce injury, triggering endothelial dysfunction.
Purpose of the Study:
- To investigate if endothelial cells are the primary target of statin therapy.
- To explore statin's effects in both hypercholesterolemia and normocholesterolemia.
- To evaluate statin's role in mitigating endothelial dysfunction.
Main Methods:
- Review of experimental and clinical studies.
- Analysis of statin's impact on endothelium-mediated functions.
- Assessment of statin's effects on nitric oxide and endothelin-1 pathways.
Main Results:
- Statins demonstrate beneficial effects on endothelium-mediated vasoactive, antithrombotic, antiproliferative, and anti-inflammatory actions.
- Evidence suggests statins positively influence endothelial function.
- Studies support the hypothesis that endothelial cells are a key target.
Conclusions:
- Endothelial cells are likely a principal target of statin therapy.
- Statins offer multifaceted benefits for endothelial health, irrespective of cholesterol levels.
- Targeting endothelial dysfunction with statins is crucial for cardiovascular disease management.
Abstract:
Endothelial dysfunction is an early event in atherosclerosis and could be considered a response to the injury induced by major risk factors. There is evidence that endothelial dysfunction is intimately involved in the onset and the progression of cardiovascular disease through abnormalities in the production, release or degradation of endothelium-derived factors, mainly nitric oxide and endothelin 1. Several reports have shown that drugs of the statin class could have multiple beneficial effects related to endothelium-mediated vasoactive, antithrombotic, antiproliferative and anti-inflammatory actions. Thus, the question arises of whether endothelial cells are the main target of statin therapy, in the setting of both hypercholesterolemia and normocholesterolemia. Experimental and clinical studies are reported that could support this hypothesis.